A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study.
Background: Survival for patients with castration-resistant prostate cancer is highly variable. We assessed the effectiveness of a whole-blood RNA transcript-based model as a prognostic biomarker in castration-resistant prostate cancer.Methods: Peripheral blood was prospectively collected from 62 me...
| Published in: | Lancet Oncology Vol. 13; no. 11; pp. 1105 - 1114 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
| Format: | research Journal Article |
| Published: |
Elsevier B.V.
Nov2012
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104378997&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 104378997 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 14702045 KH2 jtl: Lancet Oncology issn: 14702045 maglogo: N pubinfo: dt: Nov2012 vid: 13 iid: 11 ed: 1077-4114 (Print) pid: 467 pub: Elsevier B.V. place: New York, New York artinfo: ui: 104378997 104378997 NLM23059047 2011737397 10.1016/S1470-2045(12)70263-2 NLM23059047 104378997 ppf: 1105 ppct: 9 formats: tig: atl: A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. aug: au: Ross RW Galsky MD Scher HI Magidson J Wassmann K Lee GS Katz L Subudhi SK Anand A Fleisher M Kantoff PW Oh WK Ross, Robert W Galsky, Matthew D Scher, Howard I Magidson, Jay Wassmann, Karl Lee, Gwo-Shu Mary Katz, Leah Subudhi, Sumit K affil: Division of Solid Tumor Oncology, Department of Medicine, Dana-Farber Cancer Institute, Boston, MA, USA sug: subj: Prognosis Prostatic Neoplasms Blood Prostatic Neoplasms Pathology Prostatic Neoplasms Therapy RNA Blood Tumor Markers, Biological Blood Aged Aged, 80 and Over Surgery, Urogenital Human Inflammation Inflammation Metabolism Male Middle Age Prospective Studies Risk Factors Survival Analysis Aged: 65+ years Aged, 80 & over Middle Aged: 45-64 years Male ab: Background: Survival for patients with castration-resistant prostate cancer is highly variable. We assessed the effectiveness of a whole-blood RNA transcript-based model as a prognostic biomarker in castration-resistant prostate cancer.Methods: Peripheral blood was prospectively collected from 62 men with castration-resistant prostate cancer on various treatment regimens who were enrolled in a training set at the Dana-Farber Cancer Institute (Boston, MA, USA) from August, 2006, to June, 2008, and from 140 patients with castration-resistant prostate cancer in a validation set from Memorial Sloan-Kettering Cancer Center (New York, NY, USA) from August, 2006, to February, 2009. A panel of 168 inflammation-related and prostate cancer-related genes was assessed with optimised quantitative PCR to assess biomarkers predictive of survival.Findings: A six-gene model (consisting of ABL2, SEMA4D, ITGAL, and C1QA, TIMP1, CDKN1A) separated patients with castration-resistant prostate cancer into two risk groups: a low-risk group with a median survival of more than 34·9 months (median survival was not reached) and a high-risk group with a median survival of 7·8 months (95% CI 1·8-13·9; p<0·0001). The prognostic utility of the six-gene model was validated in an independent cohort. This model was associated with a significantly higher area under the curve compared with a clinicopathological model (0·90 [95% CI 0·78-0·96] vs 0·65 [0·52-0·78]; p=0·0067).Interpretation: Transcriptional profiling of whole blood yields crucial prognostic information about men with castration-resistant prostate cancer. The six-gene model suggests possible dysregulation of the immune system, a finding that warrants further study.Funding: Source MDX. pubtype: Academic Journal doctype: research Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|